ZZ BIOTECH IN THE NEWS
Featured Media Coverage
Below is media coverage about ZZ Biotech and/or 3K3A-APC.
Beyond Aduhelm: Why experts have never felt more optimistic about Alzheimer's treatments
USA Today, January 20, 2022
Australian firefighters raise funds for ALS research
PharmaVoice, January 5, 2022
Rare disease innovation in 2022
PharmaVoice, January 5, 2022
Compassionate Use Clinical Trial of FGF-1 Initiated for Amyotrophic Lateral Sclerosis
NeurologyLive, January 19, 2022
Evaluating 3K3A-APC in Patients With ALS: Kent Pryor, PhD
NeurologyLive, December 13, 2021
Discussing the Potential of 3K3A-APC as an ALS Treatment
NeurologyLive , December 11, 2021
Dosing Begins in Phase 2 Trial of 3K3A-APC to Protect Patients’ Neurons
ALS News Today, December 8, 2021
Stroke drug shows promise in treating Alzheimer’s and dementia
HSC News, December 3, 2021
First Patients Dosed in Phase 2 Trial of 3K3A-APC in ALS
NeurologyLive, December 3, 2021
Stroke Drug Might Also Prove A Powerful Tool Against Dementia
Science Blog, December 2, 2021
Firefighters fund new clinical trial for MND therapy
Mirage News, December 2, 2021
Stroke drug shows promise in treating Alzheimer’s and dementia
Mirage News, December 1, 2021